SCHEMBL5534774

SCHEMBL5534774

C#Cc1ccc(NC(=O)c2ccccc2N(C=O)c2ccc(C=NN(C)C)cc2)nc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR4 P22455 1/20 0.43
F10 P00742 4/20 0.39
NPC1 O15118 5/20 0.36
RAB9A P51151 5/20 0.36
TP53 P04637 4/20 0.36
ALOX15 P16050 1/20 0.36
HTT P42858 1/20 0.36
MAPK1 P28482 1/20 0.36
SMN1; SMN2 Q16637 6/20 0.34
ALDH1A1 P00352 3/20 0.34
LMNA P02545 3/20 0.34
GAA P10253 3/20 0.34
KDM4E B2RXH2 2/20 0.34
MAPT P10636 2/20 0.34
GLA P06280 1/20 0.34
HSD17B10 Q99714 1/20 0.34
TSHR P16473 1/20 0.33
PTBP1 P26599 1/20 0.33
SIRT2 Q8IXJ6 1/20 0.33
MEN1 O00255 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5532202 0.90 SMN1; SMN2 (0.33) FGFR4F10NPC1RAB9ATP53
SCHEMBL5533696 0.88 F10 (0.49) FGFR4F10NPC1RAB9AALOX15
SCHEMBL5531693 0.87 FGFR4 (0.38) FGFR4F10NPC1RAB9ATP53
SCHEMBL5530778 0.85 FGFR4 (0.42) FGFR4F10NPC1RAB9ATP53
SCHEMBL5534106 0.85 F10 (0.42) F10NPC1RAB9AALOX15HTT
SCHEMBL5534849 0.81 F10 (0.47) FGFR4F10SIRT2
SCHEMBL5536431 0.80 F10 (0.46) FGFR4F10SIRT2
SCHEMBL5533977 0.80 F10 (0.43) FGFR4F10NPC1RAB9AKDM4E
SCHEMBL5535739 0.79 F10 (0.46) FGFR4F10SIRT2
SCHEMBL5555100 0.79 F10 (0.46) FGFR4F10SIRT2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7312235-B2 Benzamide inhibitors of factor Xa MILLENNIUM PHARMACEUTICALS, INC. (US) 2007-12-25 US claimed
EP-1373194-B1 BENZAMIDE INHIBITORS OF FACTOR Xa MILLENNIUM PHARM INC (US) 2007-08-01 EP claimed
EP-1373194-A1 BENZAMIDE INHIBITORS OF FACTOR Xa Millennium Pharmaceuticals, Inc. (US) 2004-01-02 EP claimed
US-20030069250-A1 Benzamide inhibitors of factor Xa MILLENNIUM PHARMACEUTICALS, INC. 2003-04-10 US claimed
WO-2002079145-A1 BENZAMIDE INHIBITORS OF FACTOR Xa MILLENNIUM PHARMACEUTICALS, INC. (US) 2002-10-10 WO claimed
US-7312235-B2 Benzamide inhibitors of factor Xa MILLENNIUM PHARMACEUTICALS, INC. (US) 2007-12-25 US disclosed
EP-1373194-B1 BENZAMIDE INHIBITORS OF FACTOR Xa MILLENNIUM PHARM INC (US) 2007-08-01 EP disclosed
EP-1373194-A1 BENZAMIDE INHIBITORS OF FACTOR Xa Millennium Pharmaceuticals, Inc. (US) 2004-01-02 EP disclosed
US-20030069250-A1 Benzamide inhibitors of factor Xa MILLENNIUM PHARMACEUTICALS, INC. 2003-04-10 US disclosed
WO-2002079145-A1 BENZAMIDE INHIBITORS OF FACTOR Xa MILLENNIUM PHARMACEUTICALS, INC. (US) 2002-10-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030069250-A1 Benzamide inhibitors of factor Xa SERPINC1, TFPI, F12 FGFR4 4054/4885F10 10/4885NPC1 2635/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.